Lv71
4970 积分 2023-01-03 加入
A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
57分钟前
待确认
Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy
1小时前
待确认
Interleukin-2–based therapies in cancer
3天前
已完结
DIVERSE FUNCTIONS OF IL-2, IL-15, AND IL-7 IN LYMPHOID HOMEOSTASIS
4天前
已完结
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
5天前
已完结
Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
10天前
已完结
Understanding the tumor immune microenvironment (TIME) for effective therapy
14天前
已完结
The evolving landscape of obesity pharmacotherapy
1个月前
已完结
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
3个月前
已完结
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
4个月前
已完结
皖公网安备34019202002308
